Lynda Charters

Investigators reported that the incidence of retinal vein occlusions (RVOs) but not retinal artery occlusion, increased in the 6 months after COVID-19 diagnosis.

According to review, patients with mild diabetic retinopathy at baseline fare better.

The trial will study the effect of the drug in treatment-naïve patients with diabetic macular edema (DME) who are members of underrepresented patient populations, ie, Black, Hispanic, Latin American, and Indigenous people.

Investigators found that patients with neovascular age-related macular degeneration in all countries included in the study lost vision as a result of the lockdown and reduced number of treatments during the COVID-19 pandemic.

Study focuses on ascertaining the risk of patients developing additional tumors

Lower dose performs as effectively as a higher dose when treating ROP.

Suprachoroidal injections provide safe, effective drug delivery to target choroidal, retinal tissues.

Investigators identified that patients with moderate and severe SARS-CoV-2 pneumonia have decreased central retinal vascular density compared with patients who were asymptomatic/paucisymptomatic or control subjects.

Investigators observe survival rate with orbital retinoblastoma improves substantially due to a combination approach that includes intensive sequential treatment comprised of chemotherapy, enucleation, and external beam radiation therapy.

The implant achieves impressive efficacy and reduces treatment burden.

Luis Acaba-Berrocal, MD, of the Illinois Eye and Ear Infirmary in Chicago, worked with a group of colleagues to conduct a multicenter, retrospective, consecutive study of infants with ROP who had been treated with intravitreal anti-VEGF injections between 2008 and 2020 in light of the dearth of real-world data on the topic.

Taiichi Hikichi, MD, counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.

The first FDA-approved bispecific antibody for the eye targets two leading causes of vision loss.

Reducing the treatment burden is a prime goal for emerging AMD therapies.

Presenters at the conference provided new evidence about detecting geography atrophy and wet and dry AMD early and predicting disease progression. Investigators are also focused on finding cures for inherited retinal diseases.

Investigators at the Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy, found that the appearance of the retina and optic disc was associated with the SARS-CoV-2 virus.

Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

After 2 years, the improvements in vision and anatomy were sustained with extended dosing out to every 16 weeks in a high percentage of patients.

KALAHARI study finds THR-149 to be safe, well-tolerated with preliminary efficacy as treatment for DME patients who respond suboptimally to anti-VEGF.

Most patients (95%) with the PDS implanted did not need supplemental treatment before the refills, indicating the persistence and durability of the treatment.

Previously treated patients showed significantly reduced treatment burden.

In a presentation at the Bascom Palmer Eye Institute’s 19th annual Angiogenesis, Exudation, and Degeneration 2022 Virtual Edition, Glenn J. Jaffe, MD, noted that the analysis showed, for the first time, a decreased growth rate in the central foveal area by a therapeutic intervention when compared to sham treatment.

This study showed that an investigational subretinal implant, CPCB-RPE1, containing allogeneic human embryonic stem cell-derived RPE cells, was safe and well-tolerated by patients with dry AMD.

A once-daily oral drug targets inflammatory processes and thus far has been found to be well tolerated in a phase 2 safety trial.

Investigators search for a link between transient ischemic attacks and changes in the retina.

A study finds acceptable outcomes, vision and microperimetry improvements at higher doses.

The meeting places a special emphasis on pharmacotherapies in the pipeline for the treatment of neovascular exudative diseases of the eye and how they will affect clinical practice and Medicare.

Approach shows potential as a promising second-line screening tool for patients with diabetes.

The improvement became evident during an average time of 6 months.